*Essex Woodlands Health Ventures INC Continues to Hold Stake in Revance Therapeutics INC (RVNC)

April 20, 2018 - By Robert Judd

During 2017 Q4 the big money sentiment increased to 2.8. That’s change of 1.80, from 2017Q3’s 1. 6 investors sold all, 19 reduced holdings as RVNC ratio increased. 39 increased holdings while 31 funds amassed holdings. Funds hold 31.34 million shares thus 15.17% more from 2017Q3’s 27.21 million shares. Qs Investors owns 0.02% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 68,459 shs. D E Shaw Inc invested in 0% or 44,172 shs. Essex Invest Management Ltd Co invested in 118,952 shs or 0.56% of the stock. Wellington Group Ltd Liability Partnership holds 0.03% or 3.57 million shs. Metropolitan Life Company reported 7,537 shs. Jane Street Group Ltd Com holds 19,172 shs or 0% of its capital. Group One Trading Lp holds 0% of its capital in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 198 shs. Arrowmark Colorado Hldgs Limited Liability Corp reported 0.63% stake. Morgan Stanley reported 228,008 shs. Rhumbline Advisers, Massachusetts-based fund reported 21,276 shs. 35,454 are held by Citadel Advsr Limited Liability Com. Eam Invsts Ltd, a California-based fund reported 152,231 shs. Winch Advisory Llc invested in 200 shs. Rothschild Asset Mngmt holds 49,301 shs or 0.02% of its capital. Ameritas Inc accumulated 0% or 1,969 shs.

RVNC had 6 sales and 1 insider purchase since October 18, 2017. This’s net activity of $2.77 million. $892,412 worth of Revance Therapeutics, Inc. (NASDAQ:RVNC) was sold by SILVERNAIL LAUREN P on Tuesday, March 13. $168,045 worth of Revance Therapeutics, Inc. (NASDAQ:RVNC) was sold by GARDNER PHYLLIS. On Wednesday, October 18 Browne L Daniel had sold 7,662 shs worth $200,405.

According to 2017Q4 Securities and Exchange form the Essex Woodlands Health Ventures Inc decreased its stake in Revance Therapeutics Inc (RVNC) by 16.33%. 750,000 shares were sold by Essex Woodlands Health Ventures Inc as the company’s stock declined 12.21% with the market. The health care company at the end of 2017Q4 was valued at $137.35 million. It’s down from 4.59 million at the end of the previous reported quarter. Now it had 3.84M shares held by the hedge fund . Essex Woodlands Health Ventures Inc has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.

Analysts await Revance Therapeutics, Inc. (NASDAQ:RVNC) to report earnings on May, 8. They expect $-0.63 EPS, up 32.98 % or $0.31 from last year’s $-0.94 per share. After $-1.14 actual EPS reported by Revance Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -44.74 % EPS growth.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Ratings Coverage

In total 9 analysts cover Revance Therapeutics (NASDAQ:RVNC). “Buy” rating has 8, “Sell” are 0, while 1 are “Hold”. 89% are bullish. With $60.0 highest and $31.0 lowest [Target] Revance Therapeutics has $48.33 average [Target] or 44.92% above the current ($33.35) price. 19 are the (NASDAQ:RVNC)’s analyst reports since October 24, 2017 according to StockzIntelligence Inc. On Monday, November 27 the stock has “Buy” rating by Barclays Capital. On Monday, March 26 the firm has “Buy” rating by Needham given. On Thursday, November 16 the firm has “Buy” rating given by Cantor Fitzgerald. On Tuesday, October 24 the rating was maintained by Cantor Fitzgerald with “Buy”. On Thursday, March 1 the firm earned “Buy” rating by Piper Jaffray. On Wednesday, December 6 Mizuho maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) rating. Mizuho has “Buy” rating and $54.0 target. On Tuesday, December 5 Piper Jaffray maintained the shares of RVNC in report with “Buy” rating. On Tuesday, December 5 Guggenheim initiated the shares of RVNC in report with “Buy” rating. On Thursday, November 2 the firm has “Buy” rating by Cantor Fitzgerald given. In Thursday, January 4 report Guggenheim maintained the stock with “Buy” rating.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.